CA
BCRX icon

Corrado Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Corrado Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-49,775
Closed -$315K – 109
2016
Q4 		$315K Sell
49,775
-45,395
-48% -$236K 0.2% 82
2016
Q3 		$420K Sell
95,170
-20,530
-18% -$82K 0.27% 65
2016
Q2 		$329K Sell
115,700
-3,425
-3% -$10.6K 0.21% 71
2016
Q1 		$337K Buy
119,125
+11,230
+10% +$49.8K 0.22% 66
2015
Q4 		$1.11M Sell
107,895
-7,015
-6% -$69.8K 0.65% 36
2015
Q3 		$1.31M Buy
114,910
+86,050
+298% +$1.15M 0.74% 32
2015
Q2 		$431K Buy
+28,860
New +$328K 0.19% 63
2014
Q4 		– Sell
-14,750
Closed -$144K – 71
2014
Q3 		$144K Buy
+14,750
New +$181K 0.06% 67

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corrado Advisors's BCRX Position: Q1 2017 in Review

Corrado Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2017, closing a stake of 49,775 shares — an estimated $315K sold.

Corrado Advisors first reported a position in BCRX in Q3 2014 and held it in 8 quarters. The position peaked at $1.31M in Q3 2015. 117 funds tracked by Wall St. Rank hold BCRX as of Q1 2017.

  • Corrado Advisors reported no remaining BioCryst Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Corrado Advisors sold 49,775 BioCryst Pharmaceuticals shares in Q1 2017, an estimated $315K.
  • Corrado Advisors first reported a position in BioCryst Pharmaceuticals in Q3 2014 and held it in 8 quarters.
  • Corrado Advisors's BioCryst Pharmaceuticals position peaked at $1.31M in Q3 2015.
  • 117 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2017.

Based on Corrado Advisors's 13F filing for Q1 2017, filed 7 Apr 2017.